白蛋白紫杉醇术后辅助化疗乳腺癌患者的预后分析

Prognostic Analysis of Albumin Paclitaxel for Breast Cancer Patients after Chemotherapy

目的回顾分析乳腺癌患者于手术后的辅助化疗阶段应用白蛋白紫杉醇的效果。方法选择2020年1月—2022年12月在本院进行手术后接受辅助性化疗的100例乳腺癌患者,依据化疗方案分为对照组(表柔比星、环磷酰胺、多西他赛,50例)、治疗组(表柔比星、环磷酰胺、白蛋白紫杉醇,50例),对比相关指标。结果治疗组治疗总有效率优于对照组(P<0.05)。治疗组化疗不良反应发生率低于对照组(P<0.05);治疗组治疗后CD4+、CD3+低于对照组,差异有统计学意义(P<0.05);CD8+高于对照组,差异有统计学意义(P<0.05)。治疗组治疗后炎症反应指标均低于对照组(P<0.05)。治疗后,治疗组MK、PF4水平明显低于对照组,差异有统计学意义(P<0.05)。结论乳腺癌患者于手术后的辅助化疗阶段,应用表柔比星、环磷酰胺、白蛋白紫杉醇方案,能减少化疗相关不良反应,改善机体免疫功能、激素水平,及相关生化指标,控制炎症反应,缩短化疗时间,使病情控制效果提高。

Objective To review and analyze effect of albumin paclitaxel for breast cancer patients after chemotherapy surgery.Methods The paper chose 100 patients with breast cancer after chemotherapy surgery in our hospital from January 2020 to December 2022,and divided them into two groups according to chemotherapy scheme:control group(50 cases,with epirubicin,cyclophosphamide,docetaxel)and treatment group(50 cases,with epirubicin,cyclophosphamide,and white protein paclitaxel).Relevant indicators were compared.Results Total effective rate of treatment group was better than control group(P<0.05).Incidence of chemotherapy adverse reactions in treatment group was lower than control group(P<0.05).CD4+and CD3+levels in treatment group were significantly lower than control group after treatment(P<0.05).CD8+level was higher than control group,and difference was statistically significant(P<0.05).after treatment,inflammatory response indicators in treatment group were lower than control group(P<0.05).after treatment,levels of MK and PF4 in treatment group were significantly lower than control group,with statistically significant difference(P<0.05).Conclusion Epirubicin,cyclophosphamide and albumin paclitaxel can reduce chemotherapy related adverse reactions,improve immune function,hormone levels,and related biochemical indicators,control inflammatory reactions,shorten chemotherapy time,and improve effect of disease control of breast cancer patients at adjuvant chemotherapy stage after surgery.